Koers Inovio Pharmaceuticals Inc Nyse
Aandelen
US45773H1023
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | 604K 563K | Omzet 2025 * | 8,03 mln. 7,48 mln. | Marktkapitalisatie | 311 mln. 290 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -99 mln. -92,22 mln. | Nettowinst (verlies) 2025 * | -93 mln. -86,63 mln. | EV/omzet 2024 * | 515 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 38,7 x |
K/w-verhouding 2024 * |
-3,12
x | K/w-verhouding 2025 * |
-3,98
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,51% |
Recentste transcriptie over Inovio Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 25-03-19 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 01-06-02 |
Chief Tech/Sci/R&D Officer | - | 01-02-07 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 01-12-03 |
Lota Zoth
BRD | Director/Board Member | 64 | 01-01-18 |
Jay Shepard
BRD | Director/Board Member | 66 | 15-01-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,28% | 42,68 mld. | |
-3,99% | 42,4 mld. | |
+45,32% | 40,04 mld. | |
-6,20% | 28,31 mld. | |
+6,36% | 24,94 mld. | |
-21,47% | 18,96 mld. | |
+27,58% | 12,3 mld. | |
-2,75% | 11,95 mld. | |
-2,02% | 11,55 mld. |